Tradegate
13.10.25 | 19:42
33,500 Euro
+21,29 % +5,880
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 32,960 | 33,560 | 13.10. | |
| 32,980 | 33,540 | 13.10. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | FDA approves Teva and Medincell's bipolar I disorder treatment | 16 | Pharmaceutical Technology | ||
| Fr | Medincell: FDA Approves Expanded Indication for UZEDY (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder | 298 | Business Wire | FDA approves UZEDY (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar... ► Artikel lesen | |
| 23.09. | Teva and Medincell's Risperidone LAI Approved in Canada as LONGAVO | 397 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Teva Canada Limited, a subsidiary of Medincell's partner Teva Pharmaceutical Industries Ltd., has received regulatory approval for risperidone LAI... ► Artikel lesen | |
| 22.09. | Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed | 282 | AFX News | PETAH TIKVA (dpa-AFX) - Medincell SA (MEDCL.PA) reported that new long-term safety data from the completed Phase 3 SOLARIS trial support the potential of Olanzapine LAI (TEV-749) as the first... ► Artikel lesen | |
| 22.09. | Medincell: New Data Show that UZEDY Initiation in Hospitalized Patients is Associated with Faster Discharge and an Overall Clinician Preference Compared to Invega Sustenna | 269 | Business Wire | UZEDY was associated with a 2.89-day shorter length of hospital stay compared with Invega Sustenna (paliperidone palmitate) This translates to estimated direct cost savings of $3200 per hospitalization... ► Artikel lesen | |
| 22.09. | Medincell: New Pivotal Phase 3 Long-Term Data Supports Olanzapine Long-Acting Injectable (LAI) with Favorable Safety Profile - No PDSS Observed | 295 | Business Wire | There were no suspected or confirmed PDSS (Post-injection Delirium/Sedation Syndrome)1 events observed with Medincell's Olanzapine LAI through week 56 in the pivotal Phase 3 SOLARIS trial2 The... ► Artikel lesen | |
| 17.09. | Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation | 438 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place from September 17 21, 2025,... ► Artikel lesen | |
| MEDINCELL Aktie jetzt für 0€ handeln | |||||
| 12.09. | Medincell Appoints Three New Members to Board of Directors | 2 | Contract Pharma | ||
| 12.09. | Medincell appoints three biotech veterans to board of directors | 1 | Investing.com | ||
| 12.09. | Medincell Announces the Appointment of Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to Its Board of Directors | 446 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL) General Assembly held on September 11, 2025, has approved the appointments of three new independent board members: Dr Sharon Mates, Dr. Charles Kunsch,... ► Artikel lesen | |
| 10.09. | Medincell: UZEDY Approved in South Korea Following Successful US Launch | 342 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Teva Handok announced today that UZEDY, Long-Acting Injectable Risperidone for Schizophrenia, has received regulatory approval from the South Korean... ► Artikel lesen | |
| 05.09. | Medincell to Present at the H.C. Wainwright 27th Global Investment Conference and Participate in the Morgan Stanley 23rd Global Healthcare Conference | 442 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Christophe Douat, Chief Executive Officer, will participate along with Dr Grace Kim, Chief Strategy Officer, U.S. Finance, in the following September... ► Artikel lesen | |
| 03.09. | Medincell: Reminder of the Participation Terms in the Combined General Meeting | 407 | Business Wire | Regulatory News:
The Annual General Meeting and Extraordinary General Meeting will be held at Medincell's (Paris:MEDCL) headquarters (3 rue des Frères Lumière, 34830 Jacou, France) on Thursday... ► Artikel lesen | |
| 04.08. | Medincell: Notice of the 2025 Annual General Meeting Published | 525 | Business Wire | Regulatory News:
Medincell's (Paris:MEDCL) combined annual general meeting (ordinary and extraordinary) will be held on September 11, 2025, at 6pm at the Company's headquarters. The notice... ► Artikel lesen | |
| 30.07. | Medincell: UZEDY Accelerates: 2025 Revenue Outlook Raised to $190-$200M (from ~$160M); Olanzapine LAI on Track for Submission in 2025 | 556 | Business Wire | Regulatory News:
Medincell's (Paris:MEDCL) partner Teva Pharmaceuticals shared today the following information:
About UZEDY
1-Month and 2-Month subcutaneous risperidone for schizophrenia
Commercialized... ► Artikel lesen | |
| 30.07. | Medincell Announces the Availability of its 2024-25 Universal Registration Document including the Annual Financial and CSR Reports | 514 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
The 2024-25 Universal Registration Document (URD) filed with the French market authority (Autorités des Marchés Financiers, or AMF) under the reference... ► Artikel lesen | |
| 29.07. | Medincell Proposes Board Appointments of Industry Veterans Dr. Sharon Mates and Dr. Charles Kunsch | 624 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL):
Sharon Mates, PhD, is the co-founder and former Chair and CEO of Intra-Cellular Therapies, a CNS-focused biotech that developed the successful... ► Artikel lesen | |
| 24.07. | Medincell: Half-Year Liquidity Contract Statement | 463 | Business Wire | Regulatory News:
Under the liquidity contract entrusted by Medincell (Paris:MEDCL) to Rothschild Martin Maurel, the following resources were included in the liquidity account at June 30, 2025:... ► Artikel lesen | |
| 17.06. | Medincell Publishes its Consolidated Annual Financial Results | 572 | Business Wire | (April 1st, 2024 March 31st, 2025) Consolidated financial statements for the year 2024-25 (IFRS standards) Revenues: €25.4 million, multiplied by 2.8x compared to previous year
? Other... ► Artikel lesen | |
| 10.06. | Medincell to Present 2024-2025 Annual Results on June 17, 2025 | 619 | Business Wire | Regulatory News:
Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending March 31, 2025. The results will... ► Artikel lesen |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 88,40 | +0,63 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| EVOTEC | 6,786 | +1,31 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
| MEDIGENE | 0,062 | -0,64 % | Medigene: Gericht eröffnet Insolvenzverfahren | Bei Medigene geht die Insolvenz ihren Weg: Das zuständige Amtsgericht in München hat nach Angaben der Gesellschaft vom Freitag heute das Insolvenzverfahren über das Vermögen der Medigene AG sowie der... ► Artikel lesen | |
| QIAGEN | 40,955 | +1,20 % | QIAGEN N.V. to Release Results for Q3 2025 and Hold Webcast | QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the third quarter of 2025.
Press release date time: Tuesday, November 4, shortly after 22:05... ► Artikel lesen | |
| CUREVAC | 4,636 | +0,13 % | CureVac-Aktie im Krisenmodus: Bricht jetzt alles zusammen? Anleger fürchten das Schlimmste!!! | ||
| MODERNA | 23,790 | +3,59 % | Moderna, Inc.: Moderna Presents Promising Early Data for Its Investigational Cancer Antigen Therapy at the 2025 European Society for Medical Oncology Congress | mRNA-4359 has advanced into the Phase 2 portion of the ongoing Phase 1/2 trial CAMBRIDGE, MA / ACCESS Newswire / October 12, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that clinical, safety... ► Artikel lesen | |
| PAION | 0,017 | -23,21 % | Interne Dokumente des Wirtschaftsministeriums zeigen: So lief der umstrittene Verkauf der Paion AG an chinesische Investoren ab | ||
| VALNEVA | 4,482 | +0,18 % | Valneva korrigiert Finanzziele - Hoffnung bleibt auf Lyme-Impfstoff ab 2027 | Valneva hat eine neue Kreditfazilität über bis zu 500 Millionen US-Dollar mit von Pharmakon Advisors verwalteten Fonds abgeschlossen. Eine erste Tranche von 215 Millionen US-Dollar dient zur vollständigen... ► Artikel lesen | |
| AMGEN | 253,90 | +1,58 % | Amgen Launches AmgenNow, Direct-to-patient Program; Available To Repatha Patients | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha or evolucumab. Repatha will be available through AmgenNow at a... ► Artikel lesen | |
| NOVAVAX | 7,526 | +4,98 % | Novavax hands over Nuvaxovid marketing rights to Sanofi in the EU | ||
| STRYKER | 314,60 | +0,19 % | If You Invested $100 In Stryker Stock 20 Years Ago, You Would Have This Much Today | ||
| BIOGEN | 125,85 | -0,32 % | Biogen - BIIB: Leqembi erhält Zulassungen in China & Australien! | Pullback-Setup mit Bullenflagge! Neuausrichtung bei Biogen (BIIB): Alcyone Therapeutics für rund 85 Millionen USD übernommen & Rückzug aus AAV-basierten Gentherapieprojekten! Biogen (BIIB) - ISIN US09062X1037... ► Artikel lesen | |
| BIOFRONTERA | 2,680 | -1,11 % | BIOFRONTERA AG: Jetzt zündet die nächste Kursrakete! | ||
| HEIDELBERG PHARMA | 3,010 | -1,95 % | Heidelberg Pharma: Neue Prognose für 2025 | Heidelberg Pharma hat die Prognose für das Geschäftsjahr 2025 angepasst. Aufgrund von Fokussierungs- und Kostensparmaßnahmen erwartet das Unternehmen nun Umsätze und sonstige Erträge zwischen 7,5 Millionen... ► Artikel lesen | |
| ILLUMINA | 83,03 | +2,75 % | Illumina, Inc.: Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine | Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicinesMembers leverage AI-powered dataset to accelerate... ► Artikel lesen |
Das Unternehmen MEDINCELL SA kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 33,500 Euro und damit +21,29 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MEDINCELL SA finden Sie auf Wallstreet Online.